Articles

Podcasts

Videos

PREVENTION

Today, Pfizer-BioNTech filed submitted an Emergency Use Authorization (EUA) to administer their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children under 5 years of age.

Pfizer-BioNTech Asks FDA to Authorize Omicron Bivalent COVID-19 Booster for Children Under 5 Years

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.

Experimental HIV Vaccine Elicits Broadly Neutralizing Antibodies

The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.

Lyme Disease Vaccine Shows Antibodies 6 Months after Completion

Takeda’s investigational dengue vaccine TAK-003 is currently under evaluation for preventing any dengue virus serotype in individuals 4-60 years old.

FDA Grants Priority Review for Investigational Dengue Vaccine

Priorix and M-M-R II are fully interchangeable vaccines to protect against measles, mumps, and rubella, the CDC’s Advisory Committee on Immunization Practices said.   

CDC Outlines Best Practices for Priorix for MMR Vaccination  

Sanofi and GlaxoSmithKline are the latest companies to bring their COVID-19 booster vaccine to the marketplace with the European Commission’s approval of VidPrevtyn Beta.

European Commission Approves Sanofi-GSK COVID-19 Booster VidPrevtyn

New clinical findings suggest the Pfizer-BioNTech bivalent booster elicited more neutralizing antibody titers for all tested emerging Omicron sublineages, compared to their original COVID-19 vaccine.

Pfizer-BioNTech Adapted Bivalent Booster Neutralizes Emerging Omicron Subvariants

Dynavax reported results from its phase 1 study looking at its (Tdap-1018 CpG Adjuvanted) Tetanus/Diphtheria/Pertussis booster vaccine.

Protecting Infants, Young Children by Vaccinating Teens and Adults

The intranasal, live-attenuated vaccine CodaVax-RSV was granted FDA Fast Track designation. Clinical trials are expected to launch soon.

FDA Fast-Tracks Codagenix RSV Vaccine Candidate

“In the long run, what we will have is a virus that will become endemic in
our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”

VACCINES

Latest News